The US Food and Drug Administration (FDA) is planning to regulate the use of the cannabis compound CBD in food and supplements after weighing the evidence on the compound's safety.
The FDA will decide whether regulating legal cannabis will require new agency rules or new legislation from Congress.
Cannabis products, excluding Epidiolex, are illegal at the federal level in the US, although some states allow their use.
According to Patrick Cournoyer, who heads the FDA office developing the agency's cannabis strategy, the FDA will ascertain if CBD can be safely eaten every day for a long period or during pregnancy amid concerns about future fertility.
.


Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
RBA Signals Possible Interest Rate Hike in 2026 as Inflation Pressures Persist
Italy Fines Apple €98.6 Million Over App Store Dominance
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
US and Japan Fast-Track $550 Billion Strategic Investment Initiative
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Bolsonaro Endorses Son Flavio for Brazil’s 2026 Presidential Election From Hospital
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Democratic Attorneys General Sue Trump Administration Over Proposed Limits on Gender-Affirming Care for Youth
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Asian Stock Markets Trade Flat as Holiday Liquidity Thins and BOJ Minutes Watched
UBS Warns of Short-Term Risks as Precious Metals Rally to Record Highs
Tokyo Core Inflation Stays Above BOJ Target, Strengthening Case for Further Rate Hikes 



